AbbVie has filed for approval of a regimen based on its Venclexta therapy for previously untreated patients with chronic lymphocytic leukaemia (CLL), in combination with an AstraZeneca drug. The ...
There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie’s global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback